The IRGQ Knockout A-549 Polyclonal Cells is a CRISPR/Cas9-edited polyclonal knockout population derived from the human A-549 lung adenocarcinoma epithelial cell line, featuring disruption of the IRGQ gene. The polyclonal format provides a heterogeneous pool of loss-of-function mutations, mimicking physiological complexity. This model is intended for studies on autophagy, innate immunity, and mitochondrial biology in a lung cancer background.
A-549 cells, isolated from a 58-year-old Caucasian male with lung adenocarcinoma, serve as a well-established model for non-small cell lung cancer, epithelial infection, and drug testing. Their epithelial morphology and retained signaling pathways enable investigations into autophagy-dependent processes. IRGQ knockout in this context allows dissection of molecular mechanisms underlying tumor biology and host?Cpathogen interactions.
IRGQ is an immunity-related GTPase that regulates autophagy and innate immune responses. It is transcriptionally activated by STAT1 and IRF1 downstream of IFNG signaling. IRGQ interacts with IRGM and ATG proteins, promoting LC3 lipidation and SQSTM1/p62 degradation. It also associates with mitochondrial membrane proteins, maintaining mitochondrial homeostasis. Mechanistically, IRGQ knockout is expected to disrupt autophagic flux, alter SQSTM1/p62 turnover, and impair mitochondrial quality control, while modulating sensitivity to intracellular pathogens and inflammatory signals.
In A-549 lung adenocarcinoma cells, loss of IRGQ likely affects autophagy-mediated stress responses, immune evasion, and drug sensitivity. These cells depend on autophagy for survival under nutrient deprivation and hypoxia; therefore, IRGQ disruption may enhance vulnerability to chemotherapeutics. The knockout also provides a platform to study altered innate immunity and infection susceptibility in an epithelial background, linking interferon gamma signaling to autophagic pathways.
The IRGQ Knockout A-549 Polyclonal Cells enable diverse assays: LC3 western blotting and SQSTM1/p62 degradation analysis for autophagy assessment; infection assays with intracellular pathogens for innate immunity studies; flow cytometry for apoptosis evaluation; and mitochondrial function assays. This polyclonal model supports robust, reproducible research in cancer biology, infectious disease, and immune evasion. For inquiries, please contact Ascent Research.
